IEC 2025 | The use of immunotherapy in patients with NORSE/FIRES
Aurelie Hanin, PharmD, PhD, University Hospitals Pitié Salpêtrière, Paris, France, discusses the use of immunotherapy in patients with new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES). Dr Hanin notes that while various immunotherapies are available, the optimal treatment for each patient remains uncertain. This interview took place at the 36th International Epilepsy Congress (IEC) in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think many things may be done regarding immunotherapies and we now have like a lot of options provided for this patient but we do not know yet what is the best treatment for each patient. So even inside the same clusters we still have some possibilities like anakinra, tocilizumab, IT-DEX, and all this treatment may be beneficial for the same patients. So there is a clinical trial that will be conducted in multiple centers all over the world, led by Yale University, comparing the effect of anakinra and tocilizumab in these patients...
So I think many things may be done regarding immunotherapies and we now have like a lot of options provided for this patient but we do not know yet what is the best treatment for each patient. So even inside the same clusters we still have some possibilities like anakinra, tocilizumab, IT-DEX, and all this treatment may be beneficial for the same patients. So there is a clinical trial that will be conducted in multiple centers all over the world, led by Yale University, comparing the effect of anakinra and tocilizumab in these patients. So there was a work that was also briefly presented at the IEC and could be very important to know what could be the best treatment for this patient going forward. And I think we also need to look at small reports with like emerging treatments because maybe some of them can be beneficial in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
